Novartis: US, Europe accept submissions for new MS drug

(CercleFinance.com) - US and European regulators have accepted Novartis' regulatory submissions for ofatumumab, a treatment of relapsing forms of multiple sclerosis, the Swiss drugmaker has said.


Both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company's applications for this novel B-cell therapy, it stated.

This monoclonal antibody treatment is easy to start and manage in a monthly subcutaneous injection that can be self-administered at home using an autoinjector pen, Novartis pointed out.

Copyright (c) 2020 CercleFinance.com. All rights reserved.